IRHYTHM TECHNOLOGIES INC (IRTC)
US4500561067 - Common Stock
IRTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Health Care Equipment & Supplies industry. The financial health of IRTC is average, but there are quite some concerns on its profitability. While showing a medium growth rate, IRTC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
IRTC had negative earnings in the past year.
IRTC had a negative operating cash flow in the past year.
In the past 5 years IRTC always reported negative net income.
IRTC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IRTC (-14.29%) is comparable to the rest of the industry.
IRTC's Return On Equity of -143.94% is on the low side compared to the rest of the industry. IRTC is outperformed by 76.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.29% | ||
| ROE | -143.94% | ||
| ROIC | N/A |
ROA(3y)-25.44%
ROA(5y)-20.54%
ROE(3y)-47.82%
ROE(5y)-39.32%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IRTC has a Gross Margin of 66.97%. This is in the better half of the industry: IRTC outperforms 72.92% of its industry peers.
IRTC's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for IRTC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.87%
GM growth 5Y-1.78%
2. Health
2.1 Basic Checks
IRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IRTC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IRTC has been increased compared to 5 years ago.
The debt/assets ratio for IRTC is higher compared to a year ago.
2.2 Solvency
IRTC has an Altman-Z score of 1.88. This is not the best score and indicates that IRTC is in the grey zone with still only limited risk for bankruptcy at the moment.
IRTC has a Altman-Z score of 1.88. This is comparable to the rest of the industry: IRTC outperforms 58.33% of its industry peers.
A Debt/Equity ratio of 7.13 is on the high side and indicates that IRTC has dependencies on debt financing.
IRTC has a worse Debt to Equity ratio (7.13) than 90.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.88 |
ROIC/WACCN/A
WACC9.99%
2.3 Liquidity
IRTC has a Current Ratio of 7.10. This indicates that IRTC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IRTC (7.10) is better than 80.73% of its industry peers.
IRTC has a Quick Ratio of 6.95. This indicates that IRTC is financially healthy and has no problem in meeting its short term obligations.
IRTC has a Quick ratio of 6.95. This is amongst the best in the industry. IRTC outperforms 82.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.1 | ||
| Quick Ratio | 6.95 |
3. Growth
3.1 Past
IRTC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.69%.
IRTC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.33%.
Measured over the past years, IRTC shows a very strong growth in Revenue. The Revenue has been growing by 27.31% on average per year.
EPS 1Y (TTM)-24.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.82%
Revenue 1Y (TTM)19.33%
Revenue growth 3Y22.93%
Revenue growth 5Y27.31%
Sales Q2Q%18.39%
3.2 Future
Based on estimates for the next years, IRTC will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.36% on average per year.
Based on estimates for the next years, IRTC will show a quite strong growth in Revenue. The Revenue will grow by 15.05% on average per year.
EPS Next Y18.2%
EPS Next 2Y21.24%
EPS Next 3Y21.64%
EPS Next 5Y19.36%
Revenue Next Year19.06%
Revenue Next 2Y18.58%
Revenue Next 3Y18.18%
Revenue Next 5Y15.05%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
IRTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRTC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IRTC's earnings are expected to grow with 21.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.24%
EPS Next 3Y21.64%
5. Dividend
5.1 Amount
No dividends for IRTC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IRHYTHM TECHNOLOGIES INC
NASDAQ:IRTC (5/31/2024, 7:00:02 PM)
After market: 88.21 0 (0%)88.21
+0.08 (+0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.74B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.29% | ||
| ROE | -143.94% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.97% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.13 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.1 | ||
| Quick Ratio | 6.95 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-24.69%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y18.2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)19.33%
Revenue growth 3Y22.93%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y